See the attached memorandum which explains in detail the reasons why the Constitutents Subcommitee is in violation of FACA. Hopefully, FDA will address these issues administratively so as not to necessiate other corrective actions.
CRE’s objective is to make FDA aware of its non-compliance with FACA so it will not make the same mistakes when it establshes the menthol subcommittee.
See CRE coverage in FDA Week
Anonymous
August 27, 2010 at 5:55 pm
HEADS I WIN — TAILS YOU LOSE
All those interested need to review the questions that TPSAC must answer on August 30. See http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/UCM224116.pdf
The CTP seems to have forgotten to read FDA guidance documents as wll as basic toxicology textbooks.